Wire · opportunities
Alumis crushed by midstage lupus flop but plots path to phase 3 for TYK2 inhibitor
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 1 September 2026 · Fusion42 review
Alumis' phase 2b lupus trial of envudeucitinib failed its primary and secondary endpoints, but the company plans to advance its TYK2 inhibitor to phase 3 focusing on a subgroup with high interferon gene signature. The decision rests on positive subgroup responses despite a 54% stock drop, with plans to discuss trial modifications with the FDA and continue development for autoimmune diseases including psoriasis and cutaneous lupus.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You cannot rely on broad population trials to validate autoimmune drugs; narrowing to interferon-high patients will open a focused market and trial path. Alumis’s route shows the value in targeting distinct molecular subgroups to rescue stalled programs.
◆ Coverage
1 source · 1 Sep 2026
◆ Related on Wire
◆ Topics